000 01130 a2200325 4500
005 20250517053626.0
264 0 _c20151209
008 201512s 0 0 eng d
022 _a1539-2864
024 7 _a10.1097/IAE.0000000000000725
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBrown, David M
245 0 0 _aReply: To PMID 24914476.
_h[electronic resource]
260 _bRetina (Philadelphia, Pa.)
_cOct 2015
300 _ae61-3 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aAngiogenesis Inhibitors
_xtherapeutic use
650 0 4 _aAntibodies, Monoclonal, Humanized
_xtherapeutic use
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aIschemia
_xdrug therapy
650 0 4 _aMale
650 0 4 _aRetinal Vein Occlusion
_xdrug therapy
650 0 4 _aVascular Endothelial Growth Factor A
_xantagonists & inhibitors
700 1 _aWykoff, Charles C
700 1 _aCroft, Daniel E
700 1 _aWong, Tien P
773 0 _tRetina (Philadelphia, Pa.)
_gvol. 35
_gno. 10
_gp. e61-3
856 4 0 _uhttps://doi.org/10.1097/IAE.0000000000000725
_zAvailable from publisher's website
999 _c25288097
_d25288097